|   View web version
Today's Geriatric Medicine e-Newsletter
Subscribe or Renew
Digital Edition
September 2021 Connect with us Facebook Twitter Sign up  |  Archive  |  Advertise
Editor's e-Note
A new radiopharmaceutical treatment for ovarian cancer, the fifth-leading cancer-related cause of death in women, has been found in preclinical trials to dramatically limit tumor growth as well as reduce mass. The research was presented at the 2021 annual meeting of the Society of Nuclear Medicine and Molecular Imaging.

In addition to reading our e-newsletter, be sure to visit Today’s Geriatric Medicine’s website at, where you’ll find news and information that’s relevant and reliable. We welcome your feedback at Follow Today’s Geriatric Medicine on Facebook and Twitter, too.

— Kate Jackson, editor
e-News Exclusive
A Promising Treatment for Ovarian Cancer

Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.

In the study, “Therapeutic Efficacy of Pb-214-labeled Trastuzumab in a Preclinical Model of Ovarian Cancer,” researchers utilized a new generator system to develop the targeted alpha therapy Pb-214-TCMC-trastuzumab to treat HER2-postive ovarian cancer. Ovarian cancer cells and mice bearing ovarian cancer tumors were split into three groups: those treated with Pb-214-TCMC-trastuzumab, those treated with Pb-214-TCMC-IgG, and an untreated control group. All groups were imaged over time to determine the effectiveness of the treatment.

Compared with the Pb-214-TCMC-IgG and control groups, the tumor signal for mice and cells treated with Pb-214-TCMC-trastuzumab decreased dramatically over the course of the study, signaling the efficacy of the therapy. There were no adverse side effects from the treatment as determined by weight loss of all animals surviving.

“The short 27-minute half-life of Pb-214 is ideal for fractioned alpha particle therapeutic applications,” according to Mike Zamiara, study author and president of Niowave Inc in East Lansing, Michigan.

Full story »
Recently in Today's Geriatric Medicine
Matters of the Heart
Find out what’s new in atrial fibrillation treatment. Read more »

Combating Chronic Pain
Cannabis has been known as an effective analgesic for centuries, if not millennia. Read more »

Targeted Exercise Reduces Risk
Research has shown that exercise is the most effective intervention for fall prevention in older adults. Read more »
Advertising Opportunities
Have a product or service you want to market to geriatricians, other physicians and the geriatric care team of professionals who treat aging patients? Are you a recruiter looking to fill the many geriatric professional openings within a facility, physician practice, or academic institution? Then utilize the reach of Today's Geriatric Medicine to accomplish your marketing goals and fill any open positions.

A resource for professionals looking for new opportunities, as well as those physicians just curious to see what's out there, our Physician Recruitment Center gives physician recruiters a powerful tool to fill partnership opportunities, academic appointments, and hospital staff positions. To support your product marketing or recruiting needs, e-mail our experienced account executives today at for more information or call 800-278-4400!
In this e-Newsletter
Other Geriatrics News
Staffing Shortages in Home Care
Home care staffing shortages aren’t new, but the problem has been magnified by the pandemic. The New York Times reports on the role the quarantine played and the larger problem of increasing demand.

What’s Junk DNA Got to Do With Aging?
Washington State University researchers have explored the manner by which the telomerase gene is activated and regulated, with implications for understanding of how cancer spreads and how humans age. A DNA region directs the activity of the telomerase gene, according to the researchers.

The Pandemic Fuels a Reevaluation of Asthma Triggers
A surprising aspect of the COVID-19 pandemic has been an extraordinary decline in asthma attacks. Doctor and hospital visits for the disease have dropped dramatically, leading doctors to reconsider the conventional wisdom about the common chronic disease. The Atlantic reports on this unexpected silver lining.

Disparities in Hospital Adverse Effects
Black patients outpace white patients of the same gender and age in experiencing injuries and acquiring infections in hospitals. While prior research suggested that the disparity had to do differences in quality at the hospitals where Black and white patients are treated, new research, according to The Philadelphia Inquirer, indicates the rates are different even when Black and white patients are treated at the same hospital.
Products & Services
POP-Builder Rx
POP-Builder X, from Agilum Healthcare Intelligence, is a new health care analytic tool that is helping hospitals, payers, self-insured employers, and pharmacy benefit managers and life science organizations apply objective real-world data to improve outcomes and demonstrably reduce the total cost of care. Learn more »

Syn-One Test
From CND Life Sciences, Inc, the Syn-One Test is a breakthrough in diagnosing a group of neurogenerative diseases called synucleinopathies. These disorders share a common pathologic marker, an abnormal form of a protein, alpha-synuclein, that accumulates in nerve cells and causes progressive decline in neurological functions. Syn-One is the only commercially available test that uses a simple skin biopsy to make it easy for physicians and patients to obtain visual, pathological proof of abnormal alpha-synuclein. Learn more »
Set up Job Alerts and create your online Résumé
to let potential employers find you today!